News about "semaglutide "

HAB Pharmaceuticals Charts Growth Path, Targets INR 2,500 to 3,000 Crore Revenue by 2030

HAB Pharmaceuticals is expanding its manufacturing and R&D capabilities while strengthening its specialty product portfolio and global regulatory footprint as it targets revenues of INR 2,500–3,000 crore by 2030.

Semaglutide | 29/07/2026 | By News Bureau

Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication

Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.

Semaglutide | 21/07/2026 | By News Bureau

Torrent Pharma Recalls Select Semalix Injection Batches Following API-Related Quality Issue

Torrent Pharmaceuticals has initiated a recall of select batches of Semalix Injection 2 mg and 4 mg after certain semaglutide batches failed quality specifications due to an API-related issue.

Semaglutide | 10/07/2026 | By News Bureau |  170

Beyond the GLP-1 Boom...

The rise of GLP-1 therapies has transformed diabetes and obesity treatment. Following semaglutide patent expiry in India in March 2026, multiple companies entered the market simultaneously. Pharma Industrial India spoke with industry leaders about the opportunities, challenges, and future of this rapidly evolving therapeutic segment.

Semaglutide | 26/06/2026 | By Akanki |  129

Alkem Brings Semaglutide Pre-Filled Syringes to Indian Market

Alkem has launched semaglutide pre-filled syringes in India, introducing a convenient single-shot administration option for the management of Type 2 Diabetes (T2D) and obesity.

Semaglutide | 03/06/2026 | By News Bureau |  120

US FDA Proposes Excluding Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List

The US Food and Drug Administration (FDA) proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for compounding these GLP-1 drugs by outsourcing facilities.

Semaglutide | 04/05/2026 | By News Bureau |  121

OneSource and Orbicular Receive US FDA Tentative Approval for Generic Semaglutide

OneSource and Orbicular secure US FDA tentative approval for generic semaglutide injection, advancing ANDA filing for Ozempic with manufacturing support from OneSource.

Semaglutide | 22/04/2026 | By News Bureau |  250

PrecisionLife and Ovation Partner to Launch GLP-1 stratification LDT and GLP-1 DNA Test in H2 2026

PrecisionLife and Ovation partner to launch GLP-1 stratification LDT and consumer DNA test in 2026, with early data showing distinct genetic markers for weight loss and glycemic control.

Semaglutide | 16/04/2026 | By News Bureau |  117

UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment

The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.

Semaglutide | 15/04/2026 | By News Bureau |  189

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Semaglutide | 09/04/2026 | By News Bureau |  232